Personalized Treatment is Better than one Treatment Fits All in the Management of Patients with mCRC: A Consensus Statement

Yalçın, Şuayib; Trad, Diaeddine; Kader, Yasser Abdel; Halawani, H.; Demir, Osman; Mall, Riaz; Meshcheryakov, Andrey; Nasr, Fadi; Nosworthy, A.; Osinsky, Dmitry; Tumanova, Assel; Turhal, Serdar; Tejpar, Sabine; Köhne, Claus‐Henning

doi:10.2217/fon.14.203

Cited by 6 publications

(3 citation statements)

References 85 publications

(100 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chemotherapeutic drugs based on 5-FU and oxaliplatin do not sufficiently control the progression of advanced CRC ( 33 ). Molecular targeted drugs such as EGFR/VEGFR inhibitors offer hope for patients with advanced CRC ( 34 ), but the prognosis of advanced patients with CRC remains poor. Conventional tumor markers such as CEA and CA19-9 cannot suitably predict the occurrence and development of tumors due to poor sensitivity ( 1 ).…”

Section: Discussionmentioning

confidence: 99%

miR‑451 suppresses the malignant characteristics of colorectal cancer via targeting SAMD4B

Liu

et al. 2021

Mol Med Rep

View full text Add to dashboard Cite

Cancer metastasis and recurrence are major causes of poor survival in patients with colorectal cancer (CRC). Therefore, the biological behavior of microRNA (miR)-451 in CRC deserves further investigation. Reverse transcription-quantitative PCR was applied to measure the relative expression of miR-451 in blood serum specimens from patients with CRC and CRC cells. In vitro , HCT116 cells were transfected with miR-451 mimics, a miR-451 inhibitor, or SAMD4B plasmids. Proliferation, migration and apoptosis were measured using CCK-8, Transwell assays and flow cytometry, respectively. Luciferase reporter assay was used to identify targets of miR-451 and western blotting performed to explore the internal mechanisms of miR-451 regulation. In vivo , the effect of miR-451 and SAMD4B plasmids on tumor growth was analyzed using a nude mouse xenograft model. Results indicated that serum miR-451 expression was lower in patients with CRC compared with healthy controls. Patients with elevated expression of miR-451 had longer survival times compared with those with low expression. Overexpression of miR-451 inhibited proliferation and migration, promoted apoptosis and enhanced the sensitivity of CRC cells to chemotherapy. SAMD4B was identified as a direct target of miR-451 using miRNA target prediction programs and dual luciferase reporter assay validated the binding site of miR-451 in the 3-′UTR region of SAMD4B. Further studies confirmed that miR-451 inhibited CRC progression via targeting SAMD4B. Results indicated that miR-451 is essential for blocking tumor growth via targeting SAMD4B in vivo and in vitro . The miR-451/SAMD4B axis may serve as a novel therapeutic target in patients with CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

miR‑451 suppresses the malignant characteristics of colorectal cancer via targeting SAMD4B

Liu

et al. 2021

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…Given the predictive significance of RAS mutations, determinination of RAS mutation status from tumor samples is now a prerequisite prior to considering treatment with anti-EGFR inhibitors. 26 Use of these agents in KRAS -mutated ( KRAS -MT) tumors has been associated with worse survival outcomes. 27 …”

Section: Predicting Response To Panitumumabmentioning

confidence: 99%

Treatment of metastatic colorectal cancer: focus on panitumumab

Tay¹,

Wong²,

Hawkes³

2015

CMAR

View full text Add to dashboard Cite

Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.

show abstract

“…Treatment of CRC usually involves surgical resection of the primary tumor(s) followed by chemotherapy and/or targeted therapy for the advanced (stage III and IV) disease[ 6 ]. New drugs approved for CRC in recent years mainly fall into the class of molecular targeted drugs, including the vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) inhibitors[ 7 ].…”

Section: Introductionmentioning

confidence: 99%

MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside

Tong

et al. 2018

WJG

166

139

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small, single-stranded, noncoding RNAs that can post-transcriptionally regulate the expression of various oncogenes and tumor suppressor genes. Dysregulated expression of many miRNAs have been shown to mediate the signaling pathways critical in the multistep carcinogenesis of colorectal cancer (CRC). MiRNAs are stable and protected from RNase-mediated degradation, thereby enabling its detection in biological fluids and archival tissues for biomarker studies. This review focuses on the role and application of miRNAs in the prognosis and therapy of CRC. While stage II CRC is potentially curable by surgical resection, a significant percentage of stage II CRC patients do develop recurrence. MiRNA biomarkers may be used to stratify such high-risk population for adjuvant chemotherapy to provide better prognoses. Growing evidence also suggests that miRNAs are involved in the metastatic process of CRC. Certain of these miRNAs may thus be used as prognostic biomarkers to identify patients more likely to have micro-metastasis, who could be monitored more closely after surgery and/or given more aggressive adjuvant chemotherapy. Intrinsic and acquired resistance to chemotherapy severely hinders successful chemotherapy in CRC treatment. Predictive miRNA biomarkers for response to chemotherapy may identify patients who will benefit the most from a particular regimen and also spare the patients from unnecessary side effects. Selection of patients to receive the new targeted therapy is becoming possible with the use of predictive miRNA biomarkers. Lastly, forced expression of tumor suppressor miRNA or silencing of oncogenic miRNA in tumors by gene therapy can also be adopted to treat CRC alone or in combination with other chemotherapeutic drugs.

show abstract

Personalized Treatment is Better than one Treatment Fits All in the Management of Patients with mCRC: A Consensus Statement

Cited by 6 publications

References 85 publications

miR‑451 suppresses the malignant characteristics of colorectal cancer via targeting SAMD4B

miR‑451 suppresses the malignant characteristics of colorectal cancer via targeting SAMD4B

Treatment of metastatic colorectal cancer: focus on panitumumab

MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside

Contact Info

Product

Resources

About